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surgery 42%). The questionnaire was sent out twelve
weeks after discharge and covered the period since. Reli-
ability was assessed by comparing the 12-week question-
naire with a cost diary which patients were asked to ﬁll
in prospectively during the ﬁrst 4 weeks after discharge.
RESULTS: The 3-month questionnaire showed a re-
sponse rate of 88%. Ninety two percent of respondents
found the questionnaire easy or very easy to ﬁll in. Rate
of completion was close to 100% for all items. Time for
completion took on average 27 minutes. Comparison
with the data collected by the prospective cost diary
showed modest to good correlation for the overlapping
period. Intraclass correlation coefﬁcients ranged from
0.57 (cost of daily drug intake) to 0.9 (hospital days).
CONCLUSIONS: The instrument showed good accep-
tance and feasibility as well as reasonable reliability when
compared to a detailed prospective cost diary. Therefore
the instrument appears to be an efﬁcient alternative for
patient oriented cost measurement. With respect to relia-
bility further suggestions for improvement of the instru-
ment were developed where indicated.
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OBJECTIVE: To perform a pharmacoepidemiologic
analysis on the utilization and cost of statins in secondary
care practice in non-experimental setting. METHODS:
The Ravenna Local Health Unit administrative database
(approximately 350,000 subjects) was used to perform 
a registry of Acute Myocardial Infarction (AMI) since
1996. The registry was made by the linkages among
patients’ baseline characteristics, hospital admissions and
drug prescriptions. A 6-month follow-up study included
all subjects discharged alive from the hospital after AMI
during the period 1996–2000. Patients with previous
AMI since 1991 and those not in the province’s databases
for the entire follow-up were excluded. Drug prescrip-
tions data were processed for statins (ATC Code C10A),
ACE-inhibitors (C09A even if associated with C09B),
beta-blockers (C07), other antihypertensives (C02, C03,
C08, C09C and C09D), as well as for aspirin (B01AC06),
antidiabetic drugs (A10A and A10B), cardiac drugs (C01)
and other antiaggregants (B01AA and B01AB,
B01AC05). Drug cost was evaluated at NHS purchase
prices. RESULTS: A total of 2265 subjects were enrolled
(446 in 1996, 440 in 1997, 443 in 1998, 443 in 1999,
and 493 in 2000). The percentage of patients prescribed
for statins increased each year (from 22.6% in 1996 to
43.8% in 2000) as well as the percentage of those pre-
scribed for aspirin (from 48.0% in 1996 to 80.5% in
2000) and beta-blockers (from 27.4% in 1996 to 41.0%
in 2000). Overall cost for statins accounted to €10,610
in 1996, €15,344 in 1997, €23,483 in 1998, €35,910 in
1999, and €45,103 in 2000. Average cost for patients pre-
scribed for statins ranged from €105.05 in 1996 to
€208.81 in 2000 and increased over each year. CON-
CLUSIONS: Evidence from secondary care practice in the
province of Ravenna highlights a trend for more frequent
use of statins, aspirin and beta-blockers after discharge
for AMI.
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OBJECTIVES: The Finnish Health For All 2000 target
set in the mid-1980s (at least 80% non-smoking) was not
realised. Actually, prevalence of smoking has remained
rather constant during the 1990s even after introduction
of over-the-counter nicotine replacement (NRT) options.
Our intent was to model cost-effectiveness of six methods
(willpower, physician advice, NRT [patch, gum, spray],
bupropion) to quit smoking as applied in Finnish health
care. METHODS: Data on efﬁcacy (% successfully quit
smoking during 12 months’ observation period) were
obtained from published meta-analyses and original arti-
cles. Cost data included only direct costs (physician visits,
medications, adverse events [occurrence 1% in each treat-
ment]). Costs were estimated using societal perspective (in
year 2000 Euros). Decision-tree based average cost-
effectiveness estimates (€/additional quitter) and incre-
mental cost-effectiveness ratios (ICER) were derived by
using Data 3.5 software. Two-way sensitivity analyses
were performed. RESULTS: Efﬁcacy of willpower (1%)
and physician advice (3%) were the lowest, followed by
NRT patch (13%) and NRT gum (18%) whereas higher
for NRT spray (24%) and bupropion (30%). Costs of
willpower were set to zero by deﬁnition. Cost per addi-
tional quitter of bupropion (€954) treatment was the
lowest, and NRT spray (€2397) the highest. Bupropion
dominated over NRT gum and spray. ICER of NRT patch
vs. physician advice was €1495 (€804 for bupropion)
whereas ICER of bupropion vs. NRT patch was €404.
Sensitivity analyses showed results were robust. CON-
CLUSIONS: Short-term decision-tree analysis suggests
that bupropion is a cost-effective option for physicians in
order to help motivated smokers to quit smoking in
Finnish health care settings.
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OBJECTIVE: To estimate cost-effectiveness of pathogen
inactivation for platelet transfusions in Dutch cardiac
surgery. We used decision-tree analysis to evaluate the
cost-effectiveness of the addition of pathogen inactivation
of pooled platelets to standard procedures for platelet
transfusion safety (such as, donor recruitment and screen-
ing). METHODS: Data on transfusions were derived
from the University Hospital Groningen (Netherlands)
for 1997. Characteristics of platelet recipients (age,
gender, survival) and data/assumptions on viral and bac-
terial risks were linked to direct and indirect costs/bene-
ﬁts of pathogen inactivation. Post-transfusion survival
was simulated with a Markov-model. Standard methods
for cost-effectiveness were used. Cost-effectiveness was
expressed in net costs per life-year gained and estimated
in baseline-, sensitivity- and scenario analysis. Sensitivity
was analysed with respect to viral risks, discard rate and
discounting. Stochastic sensitivity analysis was performed
on bacterial risks. Scenario analysis was elaborated on
judicial aspects and occurrence of a new yet unknown
virus. RESULTS: Net costs per life-year gained were
€110,000 in the baseline (90% CI: €80,000–€180,000).
Sensitivity analysis revealed that cost-effectiveness was
insensitive to viral risks, but highly sensitive to, for
example, the assumed reduction in the discard rate and
discounting of life-years gained. Sensitivity and scenario
analysis showed potential reductions in cost-effectiveness
down to €50,000 per life-year gained. CONCLUSIONS:
Given relatively high net costs per life-year gained that
are internationally accepted for blood transfusion safety
interventions, our estimated cost-effectiveness ﬁgures for
pathogen inactivation may reﬂect acceptable cost-
effectiveness in this speciﬁc area. Validation of several
crucial parameters is required, in particular the Dutch risk
for acquiring transfusion-related sepsis. Further work
should extend the model to other countries, other patient
groups (haematology) and the potential elimination of
donor testing if pathogen inactivation is to cover the
whole spectra of pathogens and blood products.
PCV35
COSTS OF STROKE:A COMPARISON OF
REGULAR CARE AND THREE EXPERIMENTAL
STROKE SERVICES IN THE NETHERLANDS
Van Exel J, Koopmanschap M
Erasmus University, Rotterdam, Netherlands
OBJECTIVES: Determine patient costs after stroke and
compare costs between regular care for stroke patients
and care organised in stroke services. METHODS:
Patient costs after stroke were calculated within the
framework of the evaluation of three experiments with
stroke services in the Netherlands. Total costs of care per
patient for the 6-month follow up were based on medical
consumption of 598 patients in 6 regions consecutively
admitted to a hospital after stroke. Care consumption and
cost data were collected for hospital, rehabilitation,
nursing home, and home care. Care consumption was
retrieved from patients’ medical records and from patient
interviews two and six months after stroke. Unit cost data
were collected at participating institutions. RESULTS: We
found that the total costs of care per patient for the 6
month follow up after stroke amount to almost €16,000
on average. Costs are dominated by institutional costs
and accommodation costs. Patients who die during the
acute phase incur less costs. For patients that survive the
acute phase, severity of disability, age, gender and place
of residence before stroke are the most important deter-
minants of costs, as they inﬂuence patients’ stroke careers.
These determinants of costs also interact. CONCLU-
SIONS: Stroke care organised in stroke service experi-
ments potentially is more effective than regular care,
although large differences in costs were found between
the three stroke services. The most efﬁcient stroke service
experiment was the one that was most successful in co-
ordinating patient ﬂow from hospital to (nursing) home,
through capacity planning and efﬁcient discharge proce-
dures. The other experiments suffered from waiting lists
for (nursing) home care, leading to “blocked beds” and
higher costs of care. The relations found between costs,
organisation of care, patient characteristics and disease
severity may be applied as building-blocks for DRGs for
stroke care.
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OBJECTIVE: The study aims to 1) estimate the costs of
hospital treatmetn and the value of lost production due
to early death associated with underweight, overweight
and obese patients, and to extrapolate the ﬁndings to
national costs and 2) estimate the potential beneﬁts of an
obesity intervention program in terms of cost-offsets.
METHODS: For the ﬁrst aim we use a retrospective
analysis of the hospital treatment episodes of a deﬁned
population with data obtained from screening of 33,196
middle-aged subjects living in Malmo, Sweden and col-
lected during a 15-year follow-up period. For the second
aim we apply a prospective cost analysis within a model-
ing framework. RESULTS: The yearly excess hospital
(somatic, psychiatric) care cost (SEK) for overweight (25-
BMI-29kg/sqm) and obesity (BMI 30kg/sqm and above)
was estimated to SEK 1300 million (US$130 million,
assuming $1 = SEK10), or about 2.3 percent of total hos-
pital care costs in Sweden. Indirect costs due to early mor-
tality for obese subjects were estimated to SEK 1200
million (US$120 million). For males at age 55+ the poten-
tial hospital costs savings, excluding costs of intervention,
that could be gained by an intervention that successfully
and sefely could alter the weight of an overweight or
obese individual to become normal weight was estimated
to SEK 30,000 (US$3,000) over 15 years. CONCLU-
SION: Hospital treatment costs are found to have a J-
